Mr. Tom Bachinski reports

VECTOR SCIENCE & THERAPEUTICS ANNOUNCES LANDMARK EXCLUSIVE CGMP MANUFACTURING AGREEMENT WITH LYOGENESIS PLUS FOR ITS PROPRIETARY PEPTIDE PORTFOLIO

Vector Science and Therapeutics Corp. has signed an exclusive licensing and manufacturing agreement with LyoGenesis Plus, a current good manufacturing practice lyophilization and manufacturing partner based in Mequon, Wis. Under the agreement, Vector licenses its proprietary biomechanical peptide delivery platform to LyoGenesis and, in return, secures an exclusive, long-term manufacturing relationship covering Vector's proprietary peptide portfolio.

This agreement supersedes and renders null the company's previously announced option to invest in LyoGenesis Plus, first disclosed on May 13, 2026. The new agreement replaces that option with a direct commercial arrangement: a technology licence to LyoGenesis in exchange for exclusive manufacturing rights of Vector's proprietary peptides.

Vector's biomechanical delivery platform incorporates nanoscale carrier technology to enable targeted delivery of peptides directly to specific tissue sites, where the device releases the peptide precisely where it is needed. This targeted-release mechanism differentiates Vector's peptide portfolio from conventional peptide therapeutics on the market today, giving Vector a suite of patent-protected peptides and a distinct competitive advantage in the rapidly evolving peptide therapeutics space.

Unlike research-grade material sold in the unregulated grey market which is often manufactured without cGMP controls and is legally required to be labelled not for human use, every peptide in Vector's portfolio will be manufactured at LyoGenesis's cGMP facility and tested for potency, purity, endotoxin levels, heavy metals and sterility prior to release, meeting pharmaceutical-grade quality standards.

Vector's proprietary peptide portfolio will be manufactured under the new agreement and distributed exclusively through physician and clinical channels.

Under the agreement, LyoGenesis will develop Vector's platform for commercial use, with all Vector peptides formulated at LyoGenesis's Mequon, Wis., facility. The facility features on-site analytical capabilities to test potency, purity, endotoxin levels, heavy metals and sterility, ensuring every batch meets rigorous quality standards before release. Depending on demand, Vector and LyoGenesis estimate they will be able to scale production to satisfy up to 800,000 vials per month with gross margins of up to 60 to 80 per cent per vial for pharma-grade, cGMP-manufactured product.

"This technology represents a fundamental shift in how peptides can be delivered and utilized therapeutically," said Tom Bachinski, chief technology officer of Vector Science and Therapeutics. "By licensing this platform to LyoGenesis while securing exclusive manufacturing rights, we're able to move from innovation to commercial scale without sacrificing control over quality or supply."

"The opportunity to work with Vector on an exclusive basis to commercialize its breakthrough technology is a complement to our technical capabilities at LyoGenesis. This is an exciting technology that allows us to better control the delivery of peptide," Ben Nelson, chief scientist and chief operating office. We are confident that with the scale-up of the plant in Mequon we will be able to meet Vector's demand."

The agreement positions Vector to capture demand in a peptide therapeutics market projected to grow significantly to approximately $185.3-billion (U.S.) by 2035 as adoption of peptide-based treatments for metabolic, oncologic and regenerative applications continues to expand. Within that space, the GLP-1 receptor agonist category which includes semaglutide and tirzepatide, both part of Vector's portfolio, is the largest and fastest-growing segment, projected to grow from approximately $82.0-billion (U.S.) in 2026 to $185.3-billion (U.S.) by 2033, a compound annual growth rate of approximately 12.4 per cent.

The licensing and manufacturing agreement strengthens Vector's position across its broader peptide portfolio, including its Valor sports medicine division, by ensuring a dedicated, high-capacity, quality-controlled, physician-channel supply chain for its patent-protected peptide technologies as they advance toward commercialization.

About Vector Science and Therapeutics Corp.

Vector Science, headquartered in Mequon, Wis., develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risks are unacceptable. The company's shares are listed on the TSX Venture Exchange under the symbol PAIN.

About LyoGenesis Plus

LyoGenesis Plus is a cGMP manufacturing and lyophilization partner providing scaled, quality-controlled production services to the life science and pharmaceutical industries.

We seek Safe Harbor.